BioCentury
ARTICLE | Emerging Company Profile

Ceronco: Gateway into the cell

Ceronco's short chain sphingolipid tech increases chemo uptake in cancer cells

April 16, 2012 7:00 AM UTC

Ceronco BioSciences B.V. is developing a short chain sphingolipid delivery technology that preferentially increases the uptake of chemotherapeutics into cancer cells, which could improve efficacy without increasing toxicity.

CEO Jeroen Rovers said many formulation technologies, including liposomal approaches, preferentially deliver chemotherapy into the tumor compared to normal tissues. "But that doesn't change how the drug is taken up into the cancer cell itself," he said...